Literature DB >> 12364326

Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein.

Qiang Fu1, Robert L Jilka, Stavros C Manolagas, Charles A O'Brien.   

Abstract

Parathyroid hormone (PTH) stimulates osteoclast formation by binding to its receptor on stromal/osteoblastic cells and stimulating the production of receptor activator of NFkappaB ligand (RANKL) and inhibiting the expression of osteoprotegerin (OPG). However, the mechanisms through which PTH regulates these genes remain unknown. Here we report that PTH stimulated RANKL gene transcription and increased RANKL mRNA stability in murine stromal/osteoblastic cells stably expressing human PTH/PTH-related protein receptor 1. PTH also potently suppressed OPG mRNA in these cells. Cycloheximide did not block the effects of PTH on RANKL but did inhibit the suppression of OPG mRNA. Activation of protein kinase A (PKA) was necessary and sufficient for the effect of PTH on both genes. Conditional expression of a dominant-negative form of the transcription factor CREB, but not c-fos or Runx2, significantly reduced PTH stimulation of RANKL. CREB activity was also required for full stimulation of RANKL by oncostatin M or 1,25-dihydroxyvitamin D(3). Dominant-negative forms of CREB and c-fos reduced the suppression of OPG by PTH. These results demonstrate that PTH directly stimulates RANKL expression via a PKA-CREB pathway and that CREB may be a central regulator of RANKL expression. Furthermore, they suggest that PTH suppression of OPG involves CREB and c-fos.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12364326     DOI: 10.1074/jbc.M208494200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  75 in total

Review 1.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

2.  Anabolic action of parathyroid hormone regulated by the β2-adrenergic receptor.

Authors:  Ryo Hanyu; Vanessa L Wehbi; Tadayoshi Hayata; Shuichi Moriya; Timothy N Feinstein; Yoichi Ezura; Masashi Nagao; Yoshitomo Saita; Hiroaki Hemmi; Takuya Notomi; Tetsuya Nakamoto; Ernestina Schipani; Shu Takeda; Kazuo Kaneko; Hisashi Kurosawa; Gerard Karsenty; Henry M Kronenberg; Jean-Pierre Vilardaga; Masaki Noda
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-25       Impact factor: 11.205

3.  Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch.

Authors:  Mark A Guthridge; Jason A Powell; Emma F Barry; Frank C Stomski; Barbara J McClure; Hayley Ramshaw; Fernando A Felquer; Mara Dottore; Daniel T Thomas; Bik To; C Glenn Begley; Angel F Lopez
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

4.  Control of the SOST bone enhancer by PTH using MEF2 transcription factors.

Authors:  Olivier Leupin; Ina Kramer; Nicole M Collette; Gabriela G Loots; François Natt; Michaela Kneissel; Hansjoerg Keller
Journal:  J Bone Miner Res       Date:  2007-12       Impact factor: 6.741

5.  Beta-arrestin2 regulates parathyroid hormone effects on a p38 MAPK and NFkappaB gene expression network in osteoblasts.

Authors:  Estelle N Bianchi; Serge L Ferrari
Journal:  Bone       Date:  2009-06-25       Impact factor: 4.398

6.  Protein kinase-A-dependent osteoprotegerin production on interleukin-1 stimulation in human gingival fibroblasts is distinct from periodontal ligament fibroblasts.

Authors:  D Hormdee; T Nagasawa; M Kiji; R Yashiro; H Kobayashi; G Koshy; K Noguchi; H Nitta; I Ishikawa
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 7.  Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential.

Authors:  Marc N Wein; Marc Foretz; David E Fisher; Ramnik J Xavier; Henry M Kronenberg
Journal:  Trends Endocrinol Metab       Date:  2018-08-24       Impact factor: 12.015

Review 8.  The potential of p38 MAPK inhibitors to modulate periodontal infections.

Authors:  Keith L Kirkwood; Carlos Rossa
Journal:  Curr Drug Metab       Date:  2009-01       Impact factor: 3.731

9.  Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency.

Authors:  Jinhu Xiong; Marilina Piemontese; Jeff D Thostenson; Robert S Weinstein; Stavros C Manolagas; Charles A O'Brien
Journal:  Bone       Date:  2014-06-14       Impact factor: 4.398

10.  Rolipram, a phosphodiesterase 4 inhibitor, stimulates inducible cAMP early repressor expression in osteoblasts.

Authors:  Eun Sook Cho; Ja Heon Yu; Mi Sun Kim; Mijung Yim
Journal:  Yonsei Med J       Date:  2005-02-28       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.